viewMaxCyte Inc

MaxCyte hails strong financial performance as it says growth is likely to accelerate in 2021

The cell engineering specialist also said it had decided the future direction of its CARMA Cell Therapies arm

MaxCyte Inc -

MaxCyte Inc (LON:MXCT) (LON:MXCL) has said its 2021 revenue growth is likely to accelerate after it weighed in with a better than expected performance for the year just gone.

The cell engineering specialist said turnover for the 12 months ended December 31, 2020, advanced by 21% to US$26.2mln – a rise it attributed to the “increasing adoption and use” of its technology.

The numbers were also buoyed by the launch of an expanded ExPERT range of disposables.

Cash and equivalents at the year-end were a very healthy US$34.8mln following the company’s successful US$30.5mln financing last May.

MaxCyte, which plans to list on Nasdaq this year, is entitled to milestone payments from drug development companies where its technology is integral to the development of a new treatment.

It is now involved with 140 programmes that could yield in excess of US$950mln.

Looking ahead, the life sciences group told investors it expected revenue growth to crank up a gear, driven by existing partners' clinical progress and the “conversion of burgeoning strategic partnership pipeline”.

"The board is confident regarding the outlook for the company and we look forward to building on MaxCyte's strong operational foundation and performance of about 25% compound annual revenue growth over the past five years,” said chief executive Doug Doerfler in a statement.

“Cell-based therapies continue to demonstrate tremendous promise in the treatment of patients with intractable disease and we believe MaxCyte's next-generation technology is uniquely placed to enable the development of these therapies."

Separately, MaxCyte revealed that it has decided the future direction of the CARMA Cell Therapies operation. It said it will focus on out-licensing CARMA platform manufacturing processes and intellectual property without further investment; this its first therapeutic candidate, MCY-M11.

“We believe strongly in the value that we have built in the CARMA platform and MCY-M11 and, although we have capped our intended investment in CARMA, we look forward to developing potential licensing opportunities for this valuable IP,” said CEO Doerfler.

The cost of the strategic change is put at roughly US$4mln.

Quick facts: MaxCyte Inc

Price: 1010 GBX

Market: AIM
Market Cap: £854.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...


MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

on 1/10/20

2 min read